Anesthesiology:
doi: 10.1097/ALN.0000000000000047
Correspondence

In Reply

Legrand, Matthieu M.D., Ph.D.; Payen, Didier M.D., Ph.D.

Free Access
Article Outline
Collapse Box

Author Information

We thank Drs. Mets and Hennrikus for their constructive and relevant comments regarding our recently published case scenario.1 They rightly underline that preoperative therapy with either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker is a recognized risk factor for postoperative acute kidney injury. More importantly, they mention this therapy as a more credible etiology of acute kidney injury than hypotension itself. We support their statement, because ACE inhibitors reduce the efferent arteriole vascular tone with decreased glomerular filtration pressure and then glomerular filtration rate, especially during episodes of hypotension.2 This mechanism of reduced glomerular filtration rate corresponds to acute kidney injury definition, which may occur even with a relatively maintained renal perfusion pressure. If these different renal targets of ACE inhibitors might have negative effect, they can also be positive especially when the renin–angiotensin system is strongly stimulated as observed in cardiac failure.3 In this context, perioperative treatment with ACE inhibitors has been shown protective for renal function.4,5 The authors thank Drs. Mets and Hennrikus for their very relevant comment, which stimulates research on continuation or not of ACE for renal and nonrenal outcome with predictable differences according to the degree of renin–angiotensin system stimulation. The second point raised by their comment concerned the use of neosynephrine, a pure α-agonist, to maintain arterial blood pressure during prolonged hypotension. We agree that it was a mistake to use such a drug instead of norepinephrine, which combines α- and β-agonist effects (which was used as second-line therapeutics). Systemic blood flow (cardiac output) and regional blood flow are expected higher with norepinephrine than with a pure α-agonist. The intention presenting this case, a frequent scenario for anesthesiologists, was to emphasize the need for an adequate preoperative cardiovascular evaluation and an adapted intraoperative hemodynamic monitoring for patient at risk of acute kidney injury. In addition to the consequences of perioperative ACE administration, this case stimulates the discussion on the “reflex” of using a pure α-receptor agonist to correct hypotension, forgetting the risk of reduction in flow. Avoidance of blinded fluid and/or vasopressors administration during major surgery may therefore reduce the need of an intensive care unit rescue and improve outcome.
Matthieu Legrand, M.D., Ph.D., Didier Payen, M.D., Ph.D.
Groupe Hospitalier St-Louis-Lariboisière-Fernand Widal, Assistance Publique - Hopitaux de Paris, and University of Paris 7 Denis Diderot, Paris, France (M.L.). matthieu.m.legrand@gmail.com
Back to Top | Article Outline

References

1. Legrand M, Payen D. Case scenario: Hemodynamic management of postoperative acute kidney injury. A. 2013;118:1446–54

2. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail. 2011;4:685–91

3. Hall JE, Guyton AC, Cowley AW Jr. Dissociation of renal blood flow and filtration rate autoregulation by renin depletion. Am J Physiol. 1977;232:F215–21

4. Ryckwaert F, Colson P, Ribstein J, Boccara G, Guillon G. Haemodynamic and renal effects of intravenous enalaprilat during coronary artery bypass graft surgery in patients with ischaemic heart dysfunction. Br J Anaesth. 2001;86:169–75

5. Drenger B, Fontes ML, Miao Y, Mathew JP, Gozal Y, Aronson S, Dietzel C, Mangano DTInvestigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. . Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: Effects on in-hospital morbidity and mortality. Circulation. 2012;126:261–9

© 2014 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.
Login

Article Tools

Share